These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 9373770

  • 1. Immune responses of Leishmania donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate formulations.
    Banduwardene R, Mullen AB, Carter KC.
    Int J Immunopharmacol; 1997 Apr; 19(4):195-203. PubMed ID: 9373770
    [Abstract] [Full Text] [Related]

  • 2. The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection.
    Carter KC, Baillie AJ, Mullen AB.
    Clin Diagn Lab Immunol; 1999 Jan; 6(1):61-5. PubMed ID: 9874665
    [Abstract] [Full Text] [Related]

  • 3. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.
    Carter KC, Mullen AB, Sundar S, Kenney RT.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3555-9. PubMed ID: 11709339
    [Abstract] [Full Text] [Related]

  • 4. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.
    Mullen AB, Lawrence CE, McFarlane E, Wei XQ, Carter KC.
    Immunology; 2006 Nov; 119(3):348-54. PubMed ID: 16879623
    [Abstract] [Full Text] [Related]

  • 5. Studies on the protective efficacy of second-generation vaccine along with standard antileishmanial drug in Leishmania donovani infected BALB/c mice.
    Joshi J, Kaur S.
    Parasitology; 2014 Apr; 141(4):554-62. PubMed ID: 24618257
    [Abstract] [Full Text] [Related]

  • 6. Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs.
    Miret JA, Moreno J, Nieto J, Carter KC, Mullen AB, Ambros L, Rodríguez C, San Andrés MI, González F.
    Exp Parasitol; 2021 Jan; 220():108033. PubMed ID: 33166530
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy.
    Carter KC, Hutchison S, Boitelle A, Murray HW, Sundar S, Mullen AB.
    Parasitology; 2005 Dec; 131(Pt 6):747-57. PubMed ID: 16336728
    [Abstract] [Full Text] [Related]

  • 9. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B.
    Mullen AB, Baillie AJ, Carter KC.
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2722-5. PubMed ID: 9756784
    [Abstract] [Full Text] [Related]

  • 10. Resistance of Leishmania donovani to sodium stibogluconate is related to the expression of host and parasite gamma-glutamylcysteine synthetase.
    Carter KC, Hutchison S, Henriquez FL, Légaré D, Ouellette M, Roberts CW, Mullen AB.
    Antimicrob Agents Chemother; 2006 Jan; 50(1):88-95. PubMed ID: 16377672
    [Abstract] [Full Text] [Related]

  • 11. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis.
    Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F.
    Eur J Immunol; 2000 Oct; 30(10):2935-43. PubMed ID: 11069076
    [Abstract] [Full Text] [Related]

  • 12. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.
    Sinha R, Roychoudhury J, Palit P, Ali N.
    Antimicrob Agents Chemother; 2015 Jan; 59(1):344-55. PubMed ID: 25367907
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis.
    Williams D, Mullen AB, Baillie AJ, Carter KC.
    J Pharm Pharmacol; 1998 Dec; 50(12):1351-6. PubMed ID: 10052848
    [Abstract] [Full Text] [Related]

  • 14. Activity of rutin, a potent flavonoid against SSG-sensitive and -resistant Leishmania donovani parasites in experimental leishmaniasis.
    Chauhan K, Kaur G, Kaur S.
    Int Immunopharmacol; 2018 Nov; 64():372-385. PubMed ID: 30245348
    [Abstract] [Full Text] [Related]

  • 15. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection.
    Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC.
    J Parasitol; 2010 Oct; 96(5):929-36. PubMed ID: 20950100
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals.
    Nieto J, Alvar J, Mullen AB, Carter KC, Rodríguez C, San Andrés MI, San Andrés MD, Baillie AJ, González F.
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2781-7. PubMed ID: 12936974
    [Abstract] [Full Text] [Related]

  • 17. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis.
    Carter KC, Sundar S, Spickett C, Pereira OC, Mullen AB.
    Antimicrob Agents Chemother; 2003 May; 47(5):1529-35. PubMed ID: 12709318
    [Abstract] [Full Text] [Related]

  • 18. Genetic control of drug-induced recovery from murine visceral leishmaniasis.
    Carter KC, Baillie AJ, Alexander J.
    J Pharm Pharmacol; 1993 Sep; 45(9):795-8. PubMed ID: 7903366
    [Abstract] [Full Text] [Related]

  • 19. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.
    Lehmann J, Enssle KH, Lehmann I, Emmendörfer A, Lohmann-Matthes ML.
    J Interferon Cytokine Res; 2000 Jan; 20(1):63-77. PubMed ID: 10670653
    [Abstract] [Full Text] [Related]

  • 20. Visceral leishmaniasis: resistance to reinfection in the liver following chemotherapy in the BALB/c mouse.
    Carter KC, Alexander J, Baillie AJ, Dolan TF.
    Exp Parasitol; 1989 May; 68(4):375-81. PubMed ID: 2542078
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.